Hypha’s PolyCYPs® enzymes have been developed to provide an easy-to-use in-vitro catalytic system for the rapid oxidation of organic molecules to generate CYP derived metabolites and oxidised derivatives of drugs and agrochemicals.

PolyCYPs® enzymes are mined from Hypha’s talented microbial biotransformation platform and capable of oxidising a wide range of substrate compounds, especially arylic/benzylic -CH, -CH2, -CH3, -tert-butyl, and iso-propyl moieties, as well as aromatic systems for phenols and epoxides. De-alkylation of N- and O-alkyl moieties is also observed.

These enzymes have been successfully used by pharma and agrochemical clients  to create scalable amounts of mammalian CYP-derived metabolites, as well as oxidised late-stage derivatives of drugs. Clients have also made use of the option to outsource screening and scale-up PolyCYP reactions to Hypha.

PolyCYPs+ Metabolite Screening Kits

PolyCYPs® enzymes are formatted into a screening kit together with aldehyde oxidase and flavo-containing monooxygenase 3, which allows the convenient and cost effective in-house testing of compounds for scalable synthesis of many oxidised drug metabolites. PolyCYPs+ kits contain 18 PolyCYPs enzymes with human AOX1 and FMO3.

Reactions are scalable either by resupply of the enzymes for production in-house, or for larger scale, production and purification is available at Hypha.

Enzymes in Hypha’s oxidation kit have been rigorously tested for biocatalytic ability against a diverse panel of substrates. So far 84% of a panel of 50 CYP substrates tested have been biotransformed by PolyCYPs enzymes to at least one metabolite.

Read more about PolyCYPs+ here

Download a poster presented at the ISSX meeting in Portland US on accessing mammalian metabolites and hydroxylated derivatives of drugs using PolyCYPs enzymes.